Rovi stock trades at EUR 58.45 with a 16.2 P/ E ratio

Published on 10/08/2026 at 17:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached EUR 357.00 million, up 13.00 percent. Rovi stock stood at EUR 58.45 on October 8, 2026, 32.59 percent below its high.

Key points in brief

Rovi traded at EUR 58.45 at Lang & Schwarz on October 8, 2026, down 1.02 percent versus EUR 59.05.
First-half 2026 revenue reached EUR 357.00 million, up 13.00 percent, while gross margin rose to 68.90 percent.
Rovi had a EUR 3.0 billion market capitalization and a 16.15 P/E ratio; nine-month results are scheduled for November 5, 2026.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ES0157261019) was trading at EUR 58.45 at Lang & Schwarz on October 8, 2026 at 5:07 p.m. CEST, down 1.02 percent versus the EUR 59.05 prior close. The same quote carried a P/E ratio of 16.2, giving the valuation figure a clear place beside the daily move.

Stock sits above yearly low

Rovi traded between its EUR 53.10 52-week low and EUR 86.70 high as of October 8, 2026. The EUR 58.45 price was 10.08 percent above the low and 32.59 percent below the high.

Trading volume stood at 54,273 shares at 4:56 p.m. CEST on October 8, 2026, compared with an average volume of 108,893 shares. The bid was EUR 58.15 and the ask EUR 58.75 at Lang & Schwarz at 5:07 p.m. CEST.

First-half growth sets the baseline

According to Yahoo Finance on July 23, 2026, total revenue increased 13.00 percent to EUR 357.00 million in the first half of 2026. Gross profit rose 21.00 percent to EUR 237.10 million, while gross margin expanded by 6.50 percentage points to 68.90 percent.

The reported period also contained a EUR 62.40 million bargain purchase gain linked to the Phoenix manufacturing facility acquisition, so the headline profit increase needs that one-off item beside it. The operating picture was broader: CDMO revenue increased 38.00 percent to EUR 106.30 million in the first half of 2026, according to the same Yahoo Finance transcript.

Valuation and market size

Rovi had a market capitalization of EUR 3.0 billion as of October 8, 2026, with a P/E ratio of 16.15. The company profile places Rovi in healthcare and specialty pharmaceuticals, while its contract manufacturing business supplied a major part of first-half growth.

Comparison with peers

Rovi: minus 1.02 percent, P/E 16.15, EUR 3.0 billion

Grifols: minus 2.41 percent, P/E 14.53, EUR 6.6 billion

Faes Farma: plus 0.32 percent, P/E 10.98, EUR 1.5 billion

Next results date is November 5

Rovi's investor calendar lists November 5, 2026, for the first nine months of 2026 financial results, according to Rovi. That date gives the market its next scheduled checkpoint after a first half shaped by revenue growth, margin expansion and the Phoenix-related one-off gain.

Trading snapshot for Rovi

Rovi was trading at EUR 58.45 at Lang & Schwarz on October 8, 2026 at 5:07 p.m. CEST, down 1.02 percent versus the EUR 59.05 prior close dated October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Rovi stock.